Hôpital de la Timone

Running trials

• Not yet recruiting

  Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

  NCT07644377· Phase 3· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Source

• Not yet recruiting

  An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM

  NCT07867886· Source

• Not yet recruiting

  Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA

  2026-525463-40-00· Phase 1/2· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Source

• Not yet recruiting

  Evaluation of the FYNA Research OPM MEG Device for Locating Epileptic Foci as Part of Pre-surgical Assessment of Epilepsy

  NCT07281222· Source

• Recruiting

  Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease

  2024-518437-28-00· Phase 3· Source

• Not yet recruiting

  PRIMUS : Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis

  NCT07647952· Source

• Not yet recruiting

  Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicenter Randomized Controlled Trial (IVT-ALL-IN)

  NCT07603440· Phase 3· Source

• Not yet recruiting

  Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG

  2025-523610-83-00· Phase 4· Source

• Recruiting

  BIO|STREAM.CSP Study

  NCT07393009· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Source

• Recruiting

  Neo-adjuvant Immunotherapy in Patients With Localized Melanoma

  NCT07230613· Phase 2· Source

• Recruiting

  LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

  NCT07202897· Phase 3· Source

• Recruiting

  Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents

  NCT05126914· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Source

• Recruiting

  Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

  NCT07243470· Phase 1/2· Source

• Recruiting

  Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

  NCT06599879· Source

• Recruiting

  Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

  NCT07407465· Phase 2· Source

• Active, not recruiting

  IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

  NCT06790706· Phase 2· Source

• Not yet recruiting

  Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

  NCT06999512· Phase 2/3· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Source

• Active, not recruiting

  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

  NCT06872125· Phase 3· Source

• Recruiting

  A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

  NCT06976268· Phase 2/3· Source

• Recruiting

  Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

  NCT06876532· Source

• Enrolling by invitation

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

  NCT06908226· Phase 3· Source

• Recruiting

  PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial

  2024-510772-20-00· Phase 2· Source

• Recruiting

  Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases

  NCT06833489· Source

• Recruiting

  Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD

  NCT03593317· Phase 2· Source

• Recruiting

  Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic

  NCT06334952· Source

• Active, not recruiting

  Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting

  NCT06639620· Source

• Active, not recruiting

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

  NCT06719141· Phase 3· Source

• Active, not recruiting

  A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

  NCT06660394· Phase 3· Source

• Active, not recruiting

  Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

  NCT06333951· Phase 1· Source

• Recruiting

  French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

  NCT06147843· Source

• Recruiting

  Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

  NCT06567015· Phase 1/2· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· Source

• Recruiting

  Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

  NCT06333314· Phase 2· Source

• Recruiting

  POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric

  NCT06275737· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

  NCT06402838· Phase 2· Source

• Recruiting

  First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

  NCT06253611· Phase 2· Source

• Recruiting

  Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

  NCT06207981· Phase 3· Source

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· Source

• Recruiting

  A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

  NCT05639413· Source

• Active, not recruiting

  ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach

  NCT05928416· Source

• Recruiting

  PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years

  NCT05387954· Phase 3· Source

• Recruiting

  A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

  NCT05862285· Phase 3· Source

• Active, not recruiting

  An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

  NCT05876754· Phase 3· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers13 recruiting
• Colorectal cancer8 recruiting
• Sarcoma7 recruiting
• Epilepsy5 recruiting
• Pancreatic cancer4 recruiting
• Head and neck cancer3 recruiting
• Heart failure3 recruiting
• Lung cancer3 recruiting
• Melanoma3 recruiting
• Neuroendocrine tumours3 recruiting
• Duchenne muscular dystrophy2 recruiting
• Gastric and esophageal cancer2 recruiting
• Kidney cancer2 recruiting
• Ovarian cancer2 recruiting
• Parkinson disease2 recruiting
• Stroke2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Amyloidosis1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Crohn's disease1 recruiting
• Endometrial cancer1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• Huntington's disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroblastoma1 recruiting
• Pompe disease1 recruiting
• Prostate cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sickle cell disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  ALS Phase II Study of NX210c

  NCT06365216· Phase 2· Source

• Completed

  A phase I of TG6050 in the treatment of patients with metastatic lung cancer

  NCT05788926· Phase 1· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

  NCT05383170· Phase 1/2· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Source

• Completed

  Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT

  NCT05524324· Source

• Completed

  Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia

  NCT05053932· Source

• Recruiting

  Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

  NCT05254171· Phase 2/3· Source

• Terminated

  A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

  NCT05256381· Phase 2· Source

• Completed

  A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

  NCT05258071· Phase 2· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease

  NCT05423522· Phase 2· Source

• Completed

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· Phase 4· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

  NCT05116202· Phase 1/2· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

  NCT04793958· Phase 3· Source

• Completed

  Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

  NCT04732494· Phase 2· Source

• Completed

  Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

  NCT04739202· Phase 2· Source

• Withdrawn

  Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy

  NCT03636958· Source

• Completed

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· Phase 2· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· Source

• Completed

  Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

  NCT03947216· Phase 2· Source

• Completed

  Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

  NCT04236609· Source

• Terminated

  Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

  NCT04217447· Phase 3· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

  NCT04216953· Phase 1/2· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

  NCT04199104· Phase 3· Source

• Completed

  Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL

  NCT04168788· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Source

• Completed

  SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

  NCT03806452· Phase 2· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Source

• Completed

  FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

  NCT03723967· Phase 2· Source

• Completed

  Phase II Study of Regorafenib as Maintenance Therapy

  NCT03793361· Phase 2· Source

• Completed

  Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

  NCT03898180· Phase 3· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

  NCT03820986· Phase 3· Source

• Completed

  Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis

  NCT03293069· Phase 2/3· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· Source

• Completed

  Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

  NCT03401060· Phase 3· Source

• Completed

  A Study of BAX 888 in Male Adults With Severe Hemophilia A

  NCT03370172· Phase 1/2· Source

• Completed

  Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

  NCT02820857· Phase 2· Source

• Completed

  Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

  NCT03179436· Phase 1/2· Source

• Completed

  Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)

  NCT02864004· Phase 3· Source

• Completed

  Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

  NCT02902029· Phase 2· Source

• Completed

  Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

  NCT02676349· Phase 2· Source

• Completed

  PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

  NCT02359968· Phase 2· Source

• Completed

  Study of Predictive Factors of Progression of Motor Neurone Disease

  NCT02360891· Source

• Recruiting

  Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

  NCT02074839· Phase 1· Source

• Completed

  Predictive Factors and Subthalamic Stimulation in Parkinson's Disease

  NCT02360683· Source

Trial sites

• AP-HM - Hopital de la Timone13 trials
• AP-HM - Hopital de la Timone - Centre d'Essais en Cancerologie0 trials
• AP-HM - Hopital de la Timone /ID# 2061280 trials
• AP-HM - Hopital de la Timone /ID# 2257791 trial
• AP-HM - Hopital de la Timone /ID# 2264070 trials
• AP-HM - Hopital de la Timone - Service de Neurologie0 trials
• Aphm - Hopital La Timone5 trials
• AP-HM - Hôpital la Timone0 trials
• APHM - Hôpital Timone1 trial
• APHM, hospital of Timone1 trial
• AP-HM Marseille (Hôpital de la Timone)1 trial
• AP-HM, TIMONE Hospital, medical oncology department1 trial
• Chirurgie Digestive - Hôpital La Timone1 trial
• Department of clinical neurophysiology, Hôpital La Timone, APHM1 trial
• Department of Epileptology and Cerebral Rhythmology, Hôpital La Timone, APHM1 trial
• Hopital de la Timone63 trials
• Hopital de la Timone - APHM1 trial
• Hôpital de la Timone, AP-HM - Service de Gastroentérologie pédiatrique1 trial
• Hôpital de la Timone, AP-HM Service d'Epileptologie et Rythmologie Cérébrale1 trial
• Hôpital de la Timone - CPCEM CIC - Bat F 1er étage0 trials
• Hôpital de la Timone, Oncologie Pédiatrique1 trial
• Hôpital de la Timone - service adulte0 trials
• Hopital de la Timone Service de cardiologie0 trials
• Hopital de la Timone - Service d'Hématologie et Oncologie Pédiatrique1 trial
• Hopital de la Timone - Service d'Oncologie médicale1 trial
• Hôpital de la Timone - Service d'oncologie pédiatrique0 trials
• Hôpital de la Timone - service d'urologie1 trial
• Hôpital de la Timone - service pédiatrie0 trials
• Hopital de la Timone (Site 0246)1 trial
• Hopital de la Timone (Site 0356)0 trials
• Hopital de la Timone (Site 0442)1 trial
• Hopital de la Timone (Site 0489)0 trials
• Hopital de la Timone (Site 0617)0 trials
• Hopital de la Timone (Site 1903)1 trial
• Hôpital la Timone18 trials
• Hôpital La Timone - APHM13 trials
• Hopital La Timone - Enfants1 trial
• Hôpital La Timone /ID# 2659321 trial
• Hôpital La Timone /ID# 2670530 trials
• Hôpital La Timone /ID# 2694210 trials
• Hôpital La Timone, Service Cardiologie1 trial
• Hopital La Timone (Site 0002)1 trial
• Hopital La Timone (Site 0302)0 trials
• Hopital La Timone (Site 0328)0 trials
• Hopital La Timone (Site 0503)0 trials
• Hopital La Timone (Site 1103)0 trials
• Hopital La Timone (Site 2103)0 trials
• Hopital La Timone (Site 2204)0 trials
• Hopital La Timone (Site 3103)0 trials
• Hopital La Timone (Site 3303)1 trial
• Hopital La Timone (Site 4103)0 trials
• Hôpital Timone4 trials
• Hôspital de la Timone1 trial
• Hospital del la Timone1 trial
• Hospital La Timone1 trial
• La Timone Hospital0 trials
• La Timone Hospital, Dermatology and cutaneous oncology department1 trial
• La Timone Hospital, Nuclear Medicine Department0 trials
• MARSEILLE-Hôpital la Timone2 trials
• Marseille Hospital / La Timone1 trial
• Neuro-oncology Department, La Timone Hospital0 trials
• SERVICE DE NEUROLOGIE, Unité Mouvement Anormaux/Centre expert Parkinson, Hopital de la Timone1 trial
• Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital de la Timone, APHM1 trial
• Service d'Oncologie Digestive, Hôpital de la Timone1 trial
• Service Epileptologie et Rythmologie Cérébrale, Hôpital La Timone1 trial
• Timone Hospital0 trials
• Timone Hospital - AP-HM1 trial
• Hôpital de la Timone7 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Epilepsy56 works · 10 trials
• Sarcoma21 works · 15 trials
• Myasthenia gravis7 works · 0 trials